We are live on ! Find out more
ATXS

Astria Therapeutics
ATXS

Delisted

ATXS was delisted on the 22nd of January, 2026.

Back to rankings

102 hedge funds and large institutions have $811M invested in Astria Therapeutics in 2024 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 38 increasing their positions, 25 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

485% more call options, than puts

Call options by funds: $51M | Put options by funds: $8.72M

184% more capital invested

Capital invested by funds: $286M → $811M (+$525M)

183% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 12

52% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 25

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

28% more funds holding

Funds holding: 80 → 102 (+22)

2.41% more ownership

Funds ownership: 102.58% → 104.98% (+2.4%)

Holders
102
Holders Change
+22
Holders Change %
+27.5%
% of All Funds
1.47%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
34
Increased
38
Reduced
25
Closed
12
Calls
$51M
Puts
$8.72M
Net Calls
+$42.3M
Net Calls Change
+$42.1M

Top Buyers

Rank Fund Capital Flow
1
TCM
TCG Crossover Management
California
+$65.7M
2
RCM
RA Capital Management
Massachusetts
+$55M
3
PA
Perceptive Advisors
New York
+$30.9M
4
State Street
State Street
Massachusetts
+$21M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$19.9M

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$12.9M
2
AC
Armistice Capital
New York
-$12.1M
3
RA
Rosalind Advisors
Ontario, Canada
-$8.67M
4
SC
Stempoint Capital
New York
-$7.8M
5
AAA
Affinity Asset Advisors
New York
-$7.73M
Name Holding Trade Value Shares
Change 		Change in
Stake
CM
26
Caption Management
Oklahoma
$4.22M +$3.74M +300,000 New
Invesco
27
Invesco
Georgia
$4.16M +$3.54M +283,962 +2,472%
Morgan Stanley
28
Morgan Stanley
New York
$3.17M -$6.59M -529,521 -70%
DCM
29
DAFNA Capital Management
California
$3.14M -$2.81M -225,743 -50%
Goldman Sachs
30
Goldman Sachs
New York
$3.01M +$2.46M +197,158 +1,204%
N
31
Nuveen
North Carolina
$2.92M +$1.31M +105,031 +103%
SC
32
Stempoint Capital
New York
$2.68M -$7.8M -626,679 -73%
Citigroup
33
Citigroup
New York
$2.23M +$1.92M +153,835 +3,245%
Rafferty Asset Management
34
Rafferty Asset Management
New York
$2.2M +$1.95M +156,529 New
ACM
35
Altium Capital Management
New York
$2.01M -$7.32M -587,468 -80%
IC
36
Ikarian Capital
Texas
$1.98M -$2.92M -234,120 -62%
Barclays
37
Barclays
United Kingdom
$1.9M +$1.07M +85,793 +174%
Charles Schwab
38
Charles Schwab
California
$1.84M +$552K +44,287 +51%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$1.83M +$471K +37,853 +41%
UBS Group
40
UBS Group
Switzerland
$1.77M +$1.12M +89,876 +248%
TI
41
Tidal Investments
Wisconsin
$1.66M +$1.47M +118,200 New
Wellington Management Group
42
Wellington Management Group
Massachusetts
$1.63M +$1.45M +116,057 New
GTC
43
Ghost Tree Capital
New York
$1.62M -$2.74M -220,000 -66%
SFM
44
Sphera Funds Management
Israel
$1.59M -$12.9M -1,038,303 -90%
Bank of America
45
Bank of America
North Carolina
$1.54M +$678K +54,436 +99%
UOC
46
UBS O'Connor
Illinois
$1.52M +$374K +30,000 +38%
Simplex Trading
47
Simplex Trading
Illinois
$1.36M +$1.01M +81,001 +517%
Marshall Wace
48
Marshall Wace
United Kingdom
$989K +$697K +55,941 +391%
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$884K +$314K +25,209 +67%
AllianceBernstein
50
AllianceBernstein
Tennessee
$695K +$615K +49,370 New
1
2
3 4 5

ATXS Hedge Fund Activity: Q1 2024 in Review

102 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q1 2024, worth a combined $811M — up 184% from $286M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new ATXS positions and 12 closed out — a net gain of 22 holders — while 38 added to existing stakes and 25 trimmed.

The largest buyer was TCG Crossover Management, opening a new position worth an estimated $65.7M. The largest seller was Sphera Funds Management, cutting an estimated $12.9M.

  • 102 institutional investors held Astria Therapeutics (ATXS) as of Q1 2024, up from 80 in Q4 2023.
  • Funds reported $811M of Astria Therapeutics stock for Q1 2024, up 184% quarter-over-quarter.
  • 34 funds opened new Astria Therapeutics positions in Q1 2024 and 12 closed out, a net change of +22 holders.
  • The largest Astria Therapeutics buyer in Q1 2024 was TCG Crossover Management, an estimated $65.7M added.
  • The largest Astria Therapeutics seller in Q1 2024 was Sphera Funds Management, an estimated $12.9M sold.

Based on aggregated 13F filings for Q1 2024.